Respiratory Infections

Investigators identified behavioral determinants of being tested for pathogen exposure, in interviewing a focus group presented with a hypothetical avian influenza outbreak.

Increased rapid antigen diagnostic testing for respiratory syncytial virus (RSV) in pediatric outpatients was associated with fewer antibiotic prescriptions for respiratory tract infections.

In 2018, the FDA approved omadacycline as a new oral/intravenous third generation tetracycline to treat Community Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Here is a clinical overview of omadacycline as well as recent phase 2 clinical trial results favoring oral omadacycline as an oral treatment option for Mycobacterium abscessus pulmonary disease.

Despite increased risk for severe outcomes, most older adults and those with comorbidities do not receive antiviral treatment for COVID-19.

New phase 3 data show that Merck’s clesrovimab (Enflonsia) maintained a favorable safety profile and supportive pharmacokinetics in high-risk children under 2 years of age during a second RSV season. The company plans to file for expanded regulatory approval.

Risk of a cardiac event was higher in older patients hospitalized for respiratory syncytial virus (RSV) infection than has been reported for influenza.

An impending deadline is coming up in early 2026 that could cause the country to lose its status. However, this can be reversible and unnecessary infections, severe disease, and deaths can be avoided. Rodney Rohde, PhD, talks about incidence rates, how we got here, and strategies to increase immunizations.

This is the first human ever known to be infected with the H5N5 strain. The infected patient was from Washington state, and was undergoing treatment for H5N5 (avian influenza) when the individual died last week.

The 2025 World Health Organization's (WHO) Global Tuberculosis Report finds progress in prevention, diagnosis, and care—but falling short of targets and curtailed by funding cuts.

Large international study reports higher A-strain protection and acceptable safety profile for quadrivalent RNA influenza vaccine.

Infectious disease specialists conducted a review of vaccine safety and effectiveness independent of the ACIP to inform vaccinating against COVID-19, RSV, and influenza during this ongoing respiratory virus season.

This form of prophylaxis showed 79% overall effectiveness across 3 European countries.

RSV vaccines protected older adults against RSV-related hospitalization over 2 seasons, although with less effectiveness for those with immunocompromise or cardiovascular disease.

In a multinational NEJM trial, a single 105-mg dose cut RSV hospitalizations by 84.2% and medically attended lower respiratory infection by 60.4% through 150 days, with safety similar to placebo.

Bird migration has started. Surveillance and early detection are key, especially as it relates to H5N1 and predicting this year's respiratory virus season.

Low vaccination rates did not rise sufficiently to attain "herd immunity" after a measles outbreak in a region in which it had been eliminated.

The Los Angeles County Department of Public Health updated the public on the specific local case and reminds everyone of the importance of vaccination to protect the community.

CDC reports 3 new cases this past week, bringing the 2025 total to 1,454 confirmed cases across 42 jurisdictions, with 37 outbreaks.

NYC officials confirm 113 cases and six deaths in Central Harlem cooling tower–linked outbreak; separate Bronx investigation underway after cases tied to hot water system.

The American College of Cardiology is providing recommendations on the influenza, COVID-19, RSV vaccinations and others.

A preventable crisis, measles, makes a dangerous comeback.

A multi-prong approach reduces inappropriate antibiotic prescribing to outpatients with upper respiratory tract infection.

Clarametyx Biosciences said its investigational antibody therapy, CMTX-101, which is in a phase 1b/2a study, remains on track for full trial enrollment by the end of 2025.

In a continuing trend from the last several years, a record number of families are opting out of vaccines.

The designation is for the company’s TXA14007, its investigational antibiotic to be studied in combination with levofloxacin.